EUVIMEDEUVIMED entdecken
Crossref

Do Parenteral Iron Therapies Preserve or Deteriorate Kidney Functions? "Iron Carboxy Maltose or Iron Sucrose?"

Turker Emre, Yalcin Gokmen

Clinical Laboratory · 2024

DOI: 10.7754/clin.lab.2024.240341 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Laboratory, 2024. Verfasst von Turker Emre und 1 weiteren Autor:innen. Hauptthemen laut MEDLINE: Ferric Oxide, Saccharated, Glomerular Filtration Rate, Maltose, Ferric Compounds.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Treatment of end stage renal disease (ESRD) is based on preserving renal functions. Since renal anemia is frequently detected, we use parenteral iron treatments in patients with chronic kidney disease (CKD). However, there need to be more precise and sufficient studies on the effect of these treatments on the rate of decrease in the glomerular filtration rate (GFR). Therefore, we conducted a study comparing the rates of change in renal function in patients who had used parenteral iron for at least five years. METHODS: Our study is a retrospective cohort study, and 180 patients with CKD (86 women, 94 men, mean age: 63.5 ± 11.4 years) who had been followed and treated in nephrology outpatient clinics for at least five years and met the study criteria were included in the study. Patients were divided into three groups for iron therapy: not receiving iron therapy, iron carboxy maltose (ICM), and iron sucrose (IS) parenterally. Each group consisted of 60 people. The first and last creatinine and GFR values were compared for a 5-year follow-up in each group. RESULTS: There was no significant difference between the two groups, those using and those not using iron, regarding creatinine increase and GFR decrease rate. Additionally, no significant difference was detected in the GFR decline rates of patients using ICM and IS. CONCLUSIONS: This study reduces the concerns that correcting anemia through parenteral iron therapy in patients with CKD may harm renal function.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ferric Oxide, SaccharatedGlomerular Filtration RateMaltoseFerric CompoundsKidneyHumansFemaleMiddle AgedMaleRetrospective StudiesAgedRenal Insufficiency, ChronicAnemia, Iron-DeficiencyKidney Failure, ChronicCreatinineGlucaric Acid

Substanzen

Ferric Oxide, SaccharatedMaltoseFerric Compoundsferric carboxymaltoseCreatinineGlucaric Acid

Zitieren

APA

Emre, T., & Gokmen, Y. (2024). Do Parenteral Iron Therapies Preserve or Deteriorate Kidney Functions? "Iron Carboxy Maltose or Iron Sucrose?". Clinical Laboratory. https://doi.org/10.7754/clin.lab.2024.240341

Vancouver

Emre T, Gokmen Y. Do Parenteral Iron Therapies Preserve or Deteriorate Kidney Functions? "Iron Carboxy Maltose or Iron Sucrose?". Clinical Laboratory. 2024. doi:10.7754/clin.lab.2024.240341

BibTeX
@article{Emre2024,
  author = {Emre, Turker and Gokmen, Yalcin},
  title = {Do Parenteral Iron Therapies Preserve or Deteriorate Kidney Functions? "Iron Carboxy Maltose or Iron Sucrose?"},
  journal = {Clinical Laboratory},
  year = {2024},
  doi = {10.7754/clin.lab.2024.240341}
}
Kostenlos starten →